Genital Herpes - Pipeline Review, H1 2018

  • ID: 4464943
  • Drug Pipelines
  • 88 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abivax SA
  • AiCuris GmbH & Co KG
  • GenVec Inc
  • NanoBio Corp
  • Profectus BioSciences Inc
  • Sanofi Pasteur SA
  • MORE
Genital Herpes - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2018, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abivax SA
  • AiCuris GmbH & Co KG
  • GenVec Inc
  • NanoBio Corp
  • Profectus BioSciences Inc
  • Sanofi Pasteur SA
  • MORE
Introduction

The Publisher's Report Coverage

Genital Herpes - Overview

Genital Herpes - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Genital Herpes - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Genital Herpes - Companies Involved in Therapeutics Development

Abivax SA

Admedus Ltd

AiCuris GmbH & Co KG

Biomere LLC

GenVec Inc

Immune Design Corp

NanoBio Corp

NanoViricides Inc

Profectus BioSciences Inc

Redbiotec AG

Sanofi Pasteur SA

Starpharma Holdings Ltd

Vaccibody AS

Vical Inc

Genital Herpes - Drug Profiles

ABX-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genital herpes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GV-2207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus [type 1, 2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus 2 vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSV-529 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pritelivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Profavax HSV-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Genital Herpes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Theravax HSV-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCLHB-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCLHM-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMTX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Genital Herpes - Dormant Projects

Genital Herpes - Discontinued Products

Genital Herpes - Product Development Milestones

Featured News & Press Releases

Jan 30, 2018: Vical Provides Update on its Genital Herpes Drug Candidate VCL-HB

May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study

May 02, 2017: Vical Provides Update On Therapeutic Vaccine HSV-2 During its Research and Development Day

Apr 19, 2017: Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial

Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data

Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months

Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging

Feb 03, 2016: Model helps decide drug dose for clinical testing

Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine

Jun 22, 2015: Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine

Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences

Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection

Oct 02, 2014: Admedus Announces Further Data From Herpes Simplex Vaccine Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Genital Herpes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Genital Herpes - Pipeline by Abivax SA, H1 2018

Genital Herpes - Pipeline by Admedus Ltd, H1 2018

Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H1 2018

Genital Herpes - Pipeline by Biomere LLC, H1 2018

Genital Herpes - Pipeline by GenVec Inc, H1 2018

Genital Herpes - Pipeline by Immune Design Corp, H1 2018

Genital Herpes - Pipeline by NanoBio Corp, H1 2018

Genital Herpes - Pipeline by NanoViricides Inc, H1 2018

Genital Herpes - Pipeline by Profectus BioSciences Inc, H1 2018

Genital Herpes - Pipeline by Redbiotec AG, H1 2018

Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2018

Genital Herpes - Pipeline by Starpharma Holdings Ltd, H1 2018

Genital Herpes - Pipeline by Vaccibody AS, H1 2018

Genital Herpes - Pipeline by Vical Inc, H1 2018

Genital Herpes - Dormant Projects, H1 2018

Genital Herpes - Dormant Projects, H1 2018 (Contd..1), H1 2018

Genital Herpes - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Genital Herpes, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abivax SA
  • Admedus Ltd
  • AiCuris GmbH & Co KG
  • Biomere LLC
  • GenVec Inc
  • Immune Design Corp
  • NanoBio Corp
  • NanoViricides Inc
  • Profectus BioSciences Inc
  • Redbiotec AG
  • Sanofi Pasteur SA
  • Starpharma Holdings Ltd
  • Vaccibody AS
  • Vica
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll